| Menorrhagia
Mirena vs Oriahnn
Side-by-side clinical, coverage, and cost comparison for menorrhagia.Deep comparison between: Mirena vs Oriahnn with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOriahnn has a higher rate of injection site reactions vs Mirena based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Oriahnn but not Mirena, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mirena
Oriahnn
At A Glance
Intrauterine (IUS)
Continuous release
Progestin IUS
Oral
Twice daily
GnRH receptor antagonist
Indications
- Menorrhagia
- Menorrhagia
- Uterine Fibroids
Dosing
Contraception Insert 52 mg LNG intrauterine system by a trained healthcare provider using aseptic technique; releases approximately 21 mcg/day initially, declining to approximately 7 mcg/day by year 8; replace by the end of the eighth year.
Menorrhagia Insert 52 mg LNG intrauterine system by a trained healthcare provider using aseptic technique; replace by the end of the fifth year if continued treatment is needed.
Menorrhagia, Uterine Fibroids One elagolix 300 mg/estradiol 1 mg/norethindrone acetate 0.5 mg capsule orally in the morning and one elagolix 300 mg capsule orally in the evening, for up to 24 months.
Contraindications
- Pregnancy or suspected pregnancy
- Intended use as post-coital (emergency) contraception
- Congenital or acquired uterine anomaly, including fibroids, distorting the uterine cavity
- Acute pelvic inflammatory disease (PID) or history of PID without a subsequent intrauterine pregnancy
- Postpartum endometritis or infected abortion within the past 3 months
- Known or suspected uterine or cervical malignancy
- Known or suspected breast cancer or other progestin-sensitive cancer, current or past
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis, including bacterial vaginosis, until infection is controlled
- Acute liver disease or liver tumor (benign or malignant)
- Conditions associated with increased susceptibility to pelvic infections
- Previously inserted IUD that has not been removed
- Hypersensitivity to any component of Mirena
- High risk of arterial, venous thrombotic, or thromboembolic disorders (including women over 35 who smoke and those with history of DVT, pulmonary embolism, vascular disease, thrombogenic cardiac conditions, hypercoagulopathies, uncontrolled hypertension, or migraine with aura over age 35)
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormonally-sensitive malignancies, or increased risk for hormonally-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to ORIAHNN or any of its components
- Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
Adverse Reactions
Most common (>=10%) Alterations of menstrual bleeding patterns (unscheduled uterine bleeding, decreased uterine bleeding, increased scheduled uterine bleeding), abdominal/pelvic pain, amenorrhea, headache/migraine, genital discharge, vulvovaginitis
Serious Ectopic pregnancy, intrauterine pregnancy, Group A Streptococcal sepsis, pelvic inflammatory disease, uterine perforation, expulsion, ovarian cysts
Postmarketing Arterial thrombotic and venous thromboembolic events (pulmonary embolism, deep vein thrombosis, stroke), device breakage, hypersensitivity (rash, urticaria, angioedema), increased blood pressure
Most common (>=5%) Hot flush, headache, fatigue, metrorrhagia
Serious Thromboembolic and vascular events, bone loss, suicidal ideation and behavior, exacerbation of mood disorders, hepatic transaminase elevations, elevated blood pressure, alopecia, changes in lipid parameters
Pharmacology
Levonorgestrel-releasing intrauterine system; works locally by thickening cervical mucus to prevent sperm passage, inhibiting sperm capacitation or survival, and altering the endometrium; ovulation is inhibited in some but not all users.
GnRH receptor antagonist combination; elagolix competitively binds GnRH receptors in the pituitary gland, suppressing LH and FSH and reducing ovarian estradiol and progesterone, with add-back estradiol/norethindrone acetate to mitigate bone loss and protect the endometrium from unopposed estrogen effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mirena
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
Oriahnn
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Mirena
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Oriahnn
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Mirena
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Oriahnn
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$20/fillfill
Mirena Co-pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
myAbbVie Assist: Women's HealthCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MirenaView full Mirena profile
OriahnnView full Oriahnn profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.